{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"Phase II - Proportion of participants achieving clinical benefit defined as hematologic improvement, complete remission (CR), partial remission (PR), marrow complete remission (Marrow CR) or stable disease (SD) by the International Working Group (IWG) 2006 criteria. Erythroid Response for pretreatment hemoglobin \\< 11 g/dl; Platelet response for subjects with a pre-treatment platelet count \\< 50 x 10\\^9/L; Neutrophil response with pretreatment absolute neutrophil count (ANC) \\< 1 x 10\\^9/L.","groups":[{"description":"Phase II: Treatment at Maximum Tolerated Dose (MTD).\n\nRuxolitinib: In Phase I, participants will be allocated to twice a day (BID) doses of 10 mg/d up to 40mg/d. The starting dose will be 10 mg/d (5mg BID). Each cohort will include up to 6 subjects. Once MTD is reached, 10 additional participants will be treated during the first stage of Phase II (stage 1) at the MTD.","id":"OG000","title":"II: Maximum Tolerated Dose - Ruxolitinib"}],"paramType":"NUMBER","populationDescription":"All participants who received ruxolitinib therapy","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Occurrence of Clinical Response","type":"PRIMARY","unitOfMeasure":"participants"}